Skip to main content
FinSpry Logo
FinSpry
ABCL logo
ABCL
(NASDAQ)
AbCellera Biologics Inc.
$11.32-- (--)
Loading... - Market loading
OverviewFinancialsForecastStatisticsDividendsHistoricalProfile

AbCellera Biologics Inc. (ABCL) Analyst Forecast

Analyst consensus ratings, 12-month price targets, and expert recommendations for AbCellera Biologics Inc. stock.

Analyst Consensus Rating

Investment consensus from 4 professional research analysts

Consensus Rating

Buy
Based on 4 unique analysts
Low Confidence3.0:1 Buy/Sell

Average Price Target

$10.67
↓ 5.74% Downside

Loading chart...

Strong Sell
Sell
Hold
Buy
Strong Buy

Latest ABCL Analyst Ratings & Recommendations

Recent analyst recommendations with rating changes and price target updates (last 90 days)

Debanjana Chatterjee
JonesTrading
BuyMaintains
$13.00
Evan Seigerman
BMO Capital
BuyMaintains
$7.00
Edmund Ingham
Forbes
SellInitiates Coverage
-
Srikripa Devarakonda
Truist
BuyReiterates
$10.00 → $12.00

Frequently Asked Questions

What is the analyst consensus rating for ABCL?

The analyst consensus rating for ABCL is "Buy" based on 4 analyst recommendations.

What is the average price target for ABCL?

The average 12-month price target for ABCL is $10.67, representing a downside of 5.7% from the current price of $11.32.

What do analyst ratings mean?

Analyst ratings indicate investment recommendations: Strong Buy and Buy are bullish signals suggesting the stock may outperform. Hold means the stock is fairly valued. Sell and Strong Sell are bearish signals suggesting potential underperformance. These ratings are based on fundamental analysis and valuation models.

What is a price target?

A price target is an analyst's projection of a stock's fair value over a specific timeframe, typically 12 months. Analysts use fundamental analysis, financial modeling, and industry comparisons to estimate where the stock should trade. Price targets can range from low (conservative) to high (optimistic) estimates.